Miroru Toyoda1, Kyoichi Kaira2,3, Masato Shino1, Koichi Sakakura1, Katsumasa Takahashi1, Yukihiro Takayasu1, Hideyuki Tominaga4, Noboru Oriuchi5, Osamu Nikkuni1,6, Masami Suzuki6, Misa Iijima7, Norifumi Tsukamoto3, Shushi Nagamori8, Yoshikatsu Kanai8, Tetsunari Oyama2, Kazuaki Chikamatsu1. 1. Department of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine and Oncology Center, Gunma University Hospital, Gunma, Japan. 2. Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Gunma University Hospital, Gunma, Japan. 3. Oncology Center, Gunma University Hospital, Gunma, Japan. 4. Department of Molecular Imaging, Gunma University Graduate School of Medicine and Oncology Center, Gunma University Hospital, Gunma, Japan. 5. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Gunma, Japan. 6. Department of Head and Neck Surgery, Gunma Prefectural Cancer Center, Gunma, Japan. 7. Department of Pathology and Clinical Laboratories, Gunma Prefectural Cancer Center, Gunma, Japan. 8. Division of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Abstract
BACKGROUND: Both L-type amino acid transporter 1 (LAT1) and CD98 are strongly expressed in primary human cancer and play essential roles in tumor growth. We studied the clinicopathological significance of LAT1 and CD98 expression in hypopharyngeal squamous cell carcinoma (SCC). METHODS: A total of 70 patients with stage III/IV disease were retrospectively reviewed. Immunohistochemical staining of tumor sections was used to examine LAT1, CD98, Ki-67, CD34, and p53. RESULTS: High LAT1 and CD98 expression were noted in 60.0% and 47.1%, respectively (p = .174). A statistically significant correlation was recognized between LAT1 and CD98 expression and both expressions were closely associated with tumor cell proliferation. Although LAT1 expression was not significantly associated with poor survival, multivariate analysis revealed high CD98 expression to be an independent prognostic factor for predicting a poor outcome. CONCLUSION: CD98 is a promising prognostic marker for predicting outcomes after surgical treatment in patients with advanced hypopharyngeal SCC.
BACKGROUND: Both L-type amino acid transporter 1 (LAT1) and CD98 are strongly expressed in primary humancancer and play essential roles in tumor growth. We studied the clinicopathological significance of LAT1 and CD98 expression in hypopharyngeal squamous cell carcinoma (SCC). METHODS: A total of 70 patients with stage III/IV disease were retrospectively reviewed. Immunohistochemical staining of tumor sections was used to examine LAT1, CD98, Ki-67, CD34, and p53. RESULTS: High LAT1 and CD98 expression were noted in 60.0% and 47.1%, respectively (p = .174). A statistically significant correlation was recognized between LAT1 and CD98 expression and both expressions were closely associated with tumor cell proliferation. Although LAT1 expression was not significantly associated with poor survival, multivariate analysis revealed high CD98 expression to be an independent prognostic factor for predicting a poor outcome. CONCLUSION:CD98 is a promising prognostic marker for predicting outcomes after surgical treatment in patients with advanced hypopharyngeal SCC.
Authors: Rokaya El Ansari; Madeleine L Craze; Maria Diez-Rodriguez; Christopher C Nolan; Ian O Ellis; Emad A Rakha; Andrew R Green Journal: Br J Cancer Date: 2018-03-16 Impact factor: 7.640
Authors: Marcus Wurlitzer; Nikolaus Möckelmann; Malte Kriegs; Maren Vens; Maryam Omidi; Konstantin Hoffer; Clara von Bargen; Christina Möller-Koop; Melanie Witt; Conrad Droste; Agnes Oetting; Hannes Petersen; Chia-Jung Busch; Adrian Münscher; Hartmut Schlüter; Till Sebastian Clauditz; Thorsten Rieckmann Journal: Cancers (Basel) Date: 2020-06-11 Impact factor: 6.639